RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN ...

Dilip Shanghvi, chairman of India's largest drugmaker Sun Pharma, told an industry gathering last week that his company sells ...

High blood pressure is one of the most common conditions affecting adults in the UK, but many sufferers could benefit from a ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and resistant hypertension.

Scientists have identified a widely prescribed hypertension drug as a potential key to extending lifespan and slowing aging.

Persistent high blood pressure occurs when patients have multiple elevated blood pressure readings over time, even while ...

Discover why high blood pressure earned its "silent killer" nickname, how it damages organs without symptoms, and the ...

The study focused on why people with severe high blood pressure often develop thickened arteries and small blood vessels in ...

NAD+ boosters can affect how certain medications like insulin, blood pressure lowering, antidepressants, and cancer ...

Pennington Biomedical Research Center's Dr. Yun Shen will lead a team to explore the use of AI for precision hypertension management in Type-2 diabetes care.

Lorundrostat is an orally-administered highly selective aldosterone synthase inhibitor that reduces aldosterone levels by inhibiting CYP11B2. The Launch-HTN trial (ClinicalTrials.gov Identifier: ...

Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...